Disitamab Vedotin Injection Clinical Trials

2 actively recruiting trials

▼ -1 trial since June 2026

Also known as: DV,RC48, DV,RC48-ADC

Pipeline

Phase 2: 1Phase 2/3: 1

Top Sponsors

RemeGen Co., Ltd.2

Indications

Cancer2
Gastroesophageal Junction Adenocarcinoma1
Gastric Cancer1
Breast Cancer1

Other2 trials

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Phase 2/3

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.